[2][3][4] The screening rates for each cell line the cytostatic and cytotoxic impact of tested substances.
[2] An automated comparison against a database of more than 88,000 pure compounds and more than 34,000 crude extracts (as of 6 January 2017[update]) is provided by the COMPARE tool, which shows a list of substances ranked by the Pearson correlation coefficients for a given test substance.
[6] The panel holds cell lines representing leukemia, melanoma, non-small-cell lung carcinoma, and cancers of the brain, ovary, breast, colon, kidney, and prostate.
[7] An examination of clones made clear that the mixup with M14 happened very early in the history of MDA-MB-435, before establishment in the Developmental Therapeutics Program.
[10][7][8][9] As of 2014[update] Hundreds of research studies still use MDA-MB-435 as model of breast cancer, even after it was officially declared to be a melanoma cell line in 2007, and even in highest-rated international peer-reviewed journals.